Page last updated: 2024-12-11

lexipafant

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

lexipafant: an imidazolyl derivative which forms part of a fused heterocyclic system [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID9804204
CHEMBL ID322832
SCHEMBL ID194598
MeSH IDM0270127

Synonyms (32)

Synonym
(s)-4-methyl-2-{methyl-[4-(2-methyl-imidazo[4,5-c]pyridin-1-ylmethyl)-benzenesulfonyl]-amino}-pentanoic acid ethyl ester
bdbm50048485
4-methyl-2-{methyl-[4-(2-methyl-imidazo[4,5-c]pyridin-1-ylmethyl)-benzenesulfonyl]-amino}-pentanoic acid ethyl ester(lexipafant (bb-882))
lexipafant (usan/inn)
139133-26-9
D04724
lexipafant
bb-882
do6 ,
CHEMBL322832 ,
unii-h14917m9yw
h14917m9yw ,
l-leucine, n-methyl-n-((4-((2-methyl-1h-imidazo(4,5-c)pyridin-1-yl)ethyl)phenyl)sulfonyl)-, ethyl ester
lexipafant [usan:inn:ban]
bb 882
n-methyl-n-((alpha-(2-methyl-1h-imidazo(4,5-c)pyridin-1-yl)-p-tolyl)sulfonyl)-l-leucine, ethyl ester
lexipafant [usan]
lexipafant [mart.]
lexipafant [inn]
lexipafant [who-dd]
lexipafant [mi]
do-6
SCHEMBL194598
ethyl4-methyl-2-[methyl-[4-[(2-methylimidazo[4,5-c]pyridin-1-yl)methyl]phenyl]sulfonylamino]pentanoate
mfcd00867802
do 6
ethyl (2s)-4-methyl-2-[methyl-[4-[(2-methylimidazo[4,5-c]pyridin-1-yl)methyl]phenyl]sulfonylamino]pentanoate
Q27279470
HY-105198
DTXSID701318348
CS-0025327
AKOS040748741

Research Excerpts

Overview

Lexipafant (BB-882) is a potent platelet-activating factor receptor antagonist that has an anti-inflammatory effect.

ExcerptReferenceRelevance
"Lexipafant (BB-882) is a potent platelet-activating factor receptor antagonist that has an anti-inflammatory effect."( The effect of lexipafant on bacterial translocation in acute necrotizing pancreatitis in rats.
Bewsey, K; Djuricin, G; Gattuso, P; Liu, Q; Nathan, C; Prinz, RA; Rossi, H; Weinstein, RA, 1999
)
1.39

Actions

Lexipafant prevented the increase in albumin leakage from blood to the mucosal interstitium and the intestinal lumen during reperfusion. Lexipafan plays a role in the prevention of adhesion formation without affecting wound healing.

ExcerptReferenceRelevance
"Lexipafant prevented the increase in albumin leakage from blood to the mucosal interstitium and the intestinal lumen during reperfusion, and the mucosal albumin leakage from the gut lumen to blood during I/R."( Beneficial effects of lexipafant, a PAF antagonist on gut barrier dysfunction caused by intestinal ischemia and reperfusion in rats.
Andersson, R; Börjesson, A; Deng, X; Lasson, A; Soltesz, V; Sun, Z; Wang, X, 2000
)
1.34
"Lexipafant plays a role in the prevention of adhesion formation without affecting wound healing."( Lexipafant inhibits postsurgical adhesion formation.
Cevikel, MH; Kozaci, LD; Ozgün, H; Sakarya, S, 2002
)
3.2

Treatment

Treatment with lexipafant 30 min and 6h after pancreatitis reduced severity of pancreatitis-associated intestinal dysfunction, associated with a diminish in systemic concentrations of IL-1 and local leukocyte recruitment.

ExcerptReferenceRelevance
"Lexipafant treatment was well tolerated."( A double-blind placebo-controlled study of an infusion of lexipafant (Platelet-activating factor receptor antagonist) in patients with severe sepsis.
Angus, B; Chaowagul, W; Curtis, L; Intaranongpai, S; Leelarasamee, A; Permpikul, C; Simpson, JA; Smith, MD; Suputtamongkol, Y; White, NJ, 2000
)
1.27
"Treatment with lexipafant 30 min and 6h after pancreatitis reduced severity of pancreatitis-associated intestinal dysfunction, associated with a diminish in systemic concentrations of IL-1 and local leukocyte recruitment."( Severity of pancreatitis-associated gut barrier dysfunction is reduced following treatment with the PAF inhibitor lexipafant.
Andersson, E; Andersson, R; Börjesson, A; Leveau, P; Sun, Z; Wang, X, 2005
)
0.88
"Treatment with lexipafant and monoclonal antibodies against ICAM-1 or PECAM-1 reduced the severity of pancreatitis-associated gut endothelial dysfunction, and decreased systemic concentrations of IL-1 and local leucocyte recruitment."( Inhibition of platelet-activating factor, intercellular adhesion molecule 1 and platelet endothelial cell adhesion molecule 1 reduces experimental pancreatitis-associated gut endothelial barrier dysfunction.
Andersson, R; Börjesson, A; Sun, Z; Wang, X, 1999
)
0.66
"Treatment with lexipafant reduced the severity of pancreatitis-associated endothelial barrier compromise, also associated with a decrease in systemic concentrations of interleukin (IL) 1. "( Treatment with lexipafant ameliorates the severity of pancreatic microvascular endothelial barrier dysfunction in rats with acute hemorrhagic pancreatitis.
Aldman, M; Andersson, R; Börjesson, A; Deng, X; Haraldsen, P; Leveau, P; Sun, Z; Wang, X, 1999
)
1.01
"Pretreatment with lexipafant, a potent PAF receptor antagonist, significantly reduced the pancreatitis-induced increase in pancreatic endothelial barrier dysfunction, pancreatic leukocyte recruitment and serum levels of IL-1 beta, although a difference persisted between animals with sham operation and pancreatitis."( Treatment with lexipafant ameliorates the severity of pancreatic microvascular endothelial barrier dysfunction in rats with acute hemorrhagic pancreatitis.
Aldman, M; Andersson, R; Börjesson, A; Deng, X; Haraldsen, P; Leveau, P; Sun, Z; Wang, X, 1999
)
0.99

Dosage Studied

ExcerptRelevanceReference
" The primary outcome measure for tolerability was the ability to complete the study on the originally assigned dosage of medication."( Randomized trial of the platelet-activating factor antagonist lexipafant in HIV-associated cognitive impairment. Neurological AIDS Research Consortium.
Epstein, LG; Kieburtz, K; Marder, K; McArthur, JC; McDermott, MP; Sacktor, N; Schifitto, G; Small, S, 1999
)
0.54
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (2)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Platelet-activating factor receptorCavia porcellus (domestic guinea pig)Ki0.00040.00040.33863.2500AID161089
Platelet-activating factor receptorHomo sapiens (human)Ki0.00040.00020.53762.2700AID161085
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (29)

Processvia Protein(s)Taxonomy
positive regulation of cellular extravasationPlatelet-activating factor receptorHomo sapiens (human)
regulation of transcription by RNA polymerase IIPlatelet-activating factor receptorHomo sapiens (human)
chemotaxisPlatelet-activating factor receptorHomo sapiens (human)
inflammatory responsePlatelet-activating factor receptorHomo sapiens (human)
immune responsePlatelet-activating factor receptorHomo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathwayPlatelet-activating factor receptorHomo sapiens (human)
parturitionPlatelet-activating factor receptorHomo sapiens (human)
response to symbiotic bacteriumPlatelet-activating factor receptorHomo sapiens (human)
lipopolysaccharide-mediated signaling pathwayPlatelet-activating factor receptorHomo sapiens (human)
positive regulation of interleukin-6 productionPlatelet-activating factor receptorHomo sapiens (human)
positive regulation of tumor necrosis factor productionPlatelet-activating factor receptorHomo sapiens (human)
inositol trisphosphate biosynthetic processPlatelet-activating factor receptorHomo sapiens (human)
G protein-coupled purinergic nucleotide receptor signaling pathwayPlatelet-activating factor receptorHomo sapiens (human)
positive regulation of neutrophil degranulationPlatelet-activating factor receptorHomo sapiens (human)
transcytosisPlatelet-activating factor receptorHomo sapiens (human)
positive regulation of translationPlatelet-activating factor receptorHomo sapiens (human)
negative regulation of blood pressurePlatelet-activating factor receptorHomo sapiens (human)
positive regulation of smooth muscle cell proliferationPlatelet-activating factor receptorHomo sapiens (human)
positive regulation of inositol phosphate biosynthetic processPlatelet-activating factor receptorHomo sapiens (human)
cellular response to gravityPlatelet-activating factor receptorHomo sapiens (human)
cellular response to cAMPPlatelet-activating factor receptorHomo sapiens (human)
cellular response to fatty acidPlatelet-activating factor receptorHomo sapiens (human)
response to dexamethasonePlatelet-activating factor receptorHomo sapiens (human)
positive regulation of leukocyte tethering or rollingPlatelet-activating factor receptorHomo sapiens (human)
positive regulation of transcytosisPlatelet-activating factor receptorHomo sapiens (human)
positive regulation of maternal process involved in parturitionPlatelet-activating factor receptorHomo sapiens (human)
positive regulation of gastro-intestinal system smooth muscle contractionPlatelet-activating factor receptorHomo sapiens (human)
cellular response to 2-O-acetyl-1-O-hexadecyl-sn-glycero-3-phosphocholinePlatelet-activating factor receptorHomo sapiens (human)
G protein-coupled receptor signaling pathwayPlatelet-activating factor receptorHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (8)

Processvia Protein(s)Taxonomy
lipopolysaccharide bindingPlatelet-activating factor receptorHomo sapiens (human)
lipopolysaccharide immune receptor activityPlatelet-activating factor receptorHomo sapiens (human)
G protein-coupled receptor activityPlatelet-activating factor receptorHomo sapiens (human)
platelet activating factor receptor activityPlatelet-activating factor receptorHomo sapiens (human)
protein bindingPlatelet-activating factor receptorHomo sapiens (human)
phospholipid bindingPlatelet-activating factor receptorHomo sapiens (human)
mitogen-activated protein kinase bindingPlatelet-activating factor receptorHomo sapiens (human)
G protein-coupled purinergic nucleotide receptor activityPlatelet-activating factor receptorHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (4)

Processvia Protein(s)Taxonomy
plasma membranePlatelet-activating factor receptorHomo sapiens (human)
membranePlatelet-activating factor receptorHomo sapiens (human)
secretory granule membranePlatelet-activating factor receptorHomo sapiens (human)
tertiary granule membranePlatelet-activating factor receptorHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (20)

Assay IDTitleYearJournalArticle
AID104509Dose required to reduce the lowering of the arterial blood pressure caused by PAF by 50 %.2001Journal of medicinal chemistry, Aug-30, Volume: 44, Issue:18
Novel azo derivatives as prodrugs of 5-aminosalicylic acid and amino derivatives with potent platelet activating factor antagonist activity.
AID112425Dosage required to inhibit PAF-induced mortality in mice by 50% through oral administration1996Journal of medicinal chemistry, Jan-19, Volume: 39, Issue:2
Design, synthesis, and structure-activity relationship studies of novel 1-[(1-acyl-4-piperidyl)methyl]-1H-2- methylimidazo[4,5-c]pyridine derivatives as potent, orally active platelet-activating factor antagonists.
AID77406The compound was evaluated for its PAF-induced vascular permeability in guinea pig when dosed intravenously1998Journal of medicinal chemistry, Jan-01, Volume: 41, Issue:1
Discovery and evaluation of a series of 3-acylindole imidazopyridine platelet-activating factor antagonists.
AID77530The compound was evaluated for its PAF-induced vascular permeability in guinea pig when dosed orally1998Journal of medicinal chemistry, Jan-01, Volume: 41, Issue:1
Discovery and evaluation of a series of 3-acylindole imidazopyridine platelet-activating factor antagonists.
AID115575Percentage of inhibition by the compound against PAF-induced mortality in mice 5 hr after intravenous administration of 1 mg/Kg1996Journal of medicinal chemistry, Jan-19, Volume: 39, Issue:2
Design, synthesis, and structure-activity relationship studies of novel 1-[(1-acyl-4-piperidyl)methyl]-1H-2- methylimidazo[4,5-c]pyridine derivatives as potent, orally active platelet-activating factor antagonists.
AID112424Dosage required to inhibit PAF-induced mortality in mice by 50% through intravenous route1996Journal of medicinal chemistry, Jan-19, Volume: 39, Issue:2
Design, synthesis, and structure-activity relationship studies of novel 1-[(1-acyl-4-piperidyl)methyl]-1H-2- methylimidazo[4,5-c]pyridine derivatives as potent, orally active platelet-activating factor antagonists.
AID182806Dose required to reduce the lowering of the arterial blood pressure caused by PAF by 50% after intravenous administration in rats1996Journal of medicinal chemistry, Jan-19, Volume: 39, Issue:2
Design, synthesis, and structure-activity relationship studies of novel 1-[(1-acyl-4-piperidyl)methyl]-1H-2- methylimidazo[4,5-c]pyridine derivatives as potent, orally active platelet-activating factor antagonists.
AID161089The compound was evaluated for its binding affinity against PAF receptor in rabbit platelet1998Journal of medicinal chemistry, Jan-01, Volume: 41, Issue:1
Discovery and evaluation of a series of 3-acylindole imidazopyridine platelet-activating factor antagonists.
AID165480Concentration required to inhibit PAF-induced maximum platelet aggregation in rabbit platelet-rich plasma1996Journal of medicinal chemistry, Jan-19, Volume: 39, Issue:2
Design, synthesis, and structure-activity relationship studies of novel 1-[(1-acyl-4-piperidyl)methyl]-1H-2- methylimidazo[4,5-c]pyridine derivatives as potent, orally active platelet-activating factor antagonists.
AID21976The compound was evaluated for its solubility in lactate buffer at pH 31998Journal of medicinal chemistry, Jan-01, Volume: 41, Issue:1
Discovery and evaluation of a series of 3-acylindole imidazopyridine platelet-activating factor antagonists.
AID18644Bioavailability in rat1998Journal of medicinal chemistry, Jan-01, Volume: 41, Issue:1
Discovery and evaluation of a series of 3-acylindole imidazopyridine platelet-activating factor antagonists.
AID180180The compound was evaluated for its PAF-induced vascular permeability in rat when dosed intravenously1998Journal of medicinal chemistry, Jan-01, Volume: 41, Issue:1
Discovery and evaluation of a series of 3-acylindole imidazopyridine platelet-activating factor antagonists.
AID115574Percentage of inhibition by the compound against PAF-induced mortality in mice 3 hr after intravenous administration of 1 mg/Kg1996Journal of medicinal chemistry, Jan-19, Volume: 39, Issue:2
Design, synthesis, and structure-activity relationship studies of novel 1-[(1-acyl-4-piperidyl)methyl]-1H-2- methylimidazo[4,5-c]pyridine derivatives as potent, orally active platelet-activating factor antagonists.
AID167806Concentration required to inhibit PAF-induced maximum aggregation by 50%2001Journal of medicinal chemistry, Aug-30, Volume: 44, Issue:18
Novel azo derivatives as prodrugs of 5-aminosalicylic acid and amino derivatives with potent platelet activating factor antagonist activity.
AID161085The compound was evaluated for its binding affinity against PAF receptor in human platelet1998Journal of medicinal chemistry, Jan-01, Volume: 41, Issue:1
Discovery and evaluation of a series of 3-acylindole imidazopyridine platelet-activating factor antagonists.
AID180181The compound was evaluated for its PAF-induced vascular permeability in rat when dosed orally1998Journal of medicinal chemistry, Jan-01, Volume: 41, Issue:1
Discovery and evaluation of a series of 3-acylindole imidazopyridine platelet-activating factor antagonists.
AID60983Inhibition of PAF-induced platelet aggregation in whole blood obtained after 4 hr from dog injected with an intravenous dose of 1 mg/Kg of compound1996Journal of medicinal chemistry, Jan-19, Volume: 39, Issue:2
Design, synthesis, and structure-activity relationship studies of novel 1-[(1-acyl-4-piperidyl)methyl]-1H-2- methylimidazo[4,5-c]pyridine derivatives as potent, orally active platelet-activating factor antagonists.
AID60984Inhibition of PAF-induced platelet aggregation in whole blood obtained after 6 hr from dog injected with an intravenous dose of 1 mg/Kg of compound1996Journal of medicinal chemistry, Jan-19, Volume: 39, Issue:2
Design, synthesis, and structure-activity relationship studies of novel 1-[(1-acyl-4-piperidyl)methyl]-1H-2- methylimidazo[4,5-c]pyridine derivatives as potent, orally active platelet-activating factor antagonists.
AID18642Bioavailability in monkey1998Journal of medicinal chemistry, Jan-01, Volume: 41, Issue:1
Discovery and evaluation of a series of 3-acylindole imidazopyridine platelet-activating factor antagonists.
AID115576Percentage of inhibition by the compound against PAF-induced mortality in mice 7 hr after intravenous administration of 1 mg/Kg1996Journal of medicinal chemistry, Jan-19, Volume: 39, Issue:2
Design, synthesis, and structure-activity relationship studies of novel 1-[(1-acyl-4-piperidyl)methyl]-1H-2- methylimidazo[4,5-c]pyridine derivatives as potent, orally active platelet-activating factor antagonists.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (66)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's30 (45.45)18.2507
2000's36 (54.55)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 29.25

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index29.25 (24.57)
Research Supply Index4.41 (2.92)
Research Growth Index4.33 (4.65)
Search Engine Demand Index32.40 (26.88)
Search Engine Supply Index1.83 (0.95)

This Compound (29.25)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials11 (15.71%)5.53%
Reviews16 (22.86%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other43 (61.43%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]